ABSTRACT N-Methyl-D-aspartate (NMDA) receptors are ligand-gated ion channels that mediate a slow, Ca 2ϩ -permeable component of excitatory synaptic transmission in the central nervous system and play a pivotal role in synaptic plasticity, neuronal development, and several neurological diseases. We describe a fluorescence-based assay that measures NMDA receptor-mediated changes in intracellular calcium in a BHK-21 cell line stably expressing NMDA receptor NR2D with NR1 under the control of a tetracycline-inducible promoter (Tet-On). The assay selectively identifies allosteric modulators by using supramaximal concentrations of glutamate and glycine to minimize detection of competitive antagonists. The assay is validated by successfully identifying known noncompetitive, but not competitive NMDA receptor antagonists among 1800 screened compounds from two small focused libraries, including the commercially available library of pharmacologically active compounds. Hits from the primary screen are validated through a secondary screen that used two-electrode voltage-clamp recordings on recombinant NMDA receptors expressed in Xenopus laevis oocytes. This strategy identified several novel modulators of NMDA receptor function, including the histamine H3 receptor antagonists clobenpropit and iodophenpropit, as well as the vanilloid receptor transient receptor potential cation channel, subfamily V, member 1 (TRPV1) antagonist capsazepine. These compounds are noncompetitive antagonists and the histamine H3 receptor ligand showed submicromolar potency at NR1/NR2B NMDA receptors, which raises the possibility that compounds can be developed that act with high potency on both glutamate and histamine receptor systems simultaneously. Furthermore, it is possible that some actions attributed to histamine H3 receptor inhibition in vivo may also involve NMDA receptor antagonism.
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-permeable component of excitatory synaptic transmission in the central nervous system and play a pivotal role in synaptic plasticity, neuronal development, and several neurological diseases. We describe a fluorescence-based assay that measures NMDA receptor-mediated changes in intracellular calcium in a BHK-21 cell line stably expressing NMDA receptor NR2D with NR1 under the control of a tetracycline-inducible promoter (Tet-On). The assay selectively identifies allosteric modulators by using supramaximal concentrations of glutamate and glycine to minimize detection of competitive antagonists. The assay is validated by successfully identifying known noncompetitive, but not competitive NMDA receptor antagonists among 1800 screened compounds from two small focused libraries, including the commercially available library of pharmacologically active compounds. Hits from the primary screen are validated through a secondary screen that used two-electrode voltage-clamp recordings on recombinant NMDA receptors expressed in Xenopus laevis oocytes. This strategy identified several novel modulators of NMDA receptor function, including the histamine H3 receptor antagonists clobenpropit and iodophenpropit, as well as the vanilloid receptor transient receptor potential cation channel, subfamily V, member 1 (TRPV1) antagonist capsazepine. These compounds are noncompetitive antagonists and the histamine H3 receptor ligand showed submicromolar potency at NR1/NR2B NMDA receptors, which raises the possibility that compounds can be developed that act with high potency on both glutamate and histamine receptor systems simultaneously. Furthermore, it is possible that some actions attributed to histamine H3 receptor inhibition in vivo may also involve NMDA receptor antagonism.
N-methyl-D-aspartate (NMDA) receptors, a class of the ionotropic glutamate receptors, are ligand-gated cation-selective channels that mediate excitatory synaptic transmission in the central nervous system (Traynelis et al., 2010) . These receptors are involved in many normal brain functions, such as neuronal development (Nacher and McEwen, 2006) , learning, and memory (Lisman, 2003) . NMDA receptors have also been implicated in a wide range of neuropathological conditions, including stroke, epilepsy, schizophrenia, depression, Huntington's disease, Alzheimer's disease, Parkinson's disease, and multiple sclerosis (Brä uner-Osborne et al., 2000; Waxman and Lynch, 2005; Traynelis et al., 2010) .
The majority of native NMDA receptors are tetramers made up of two glycine-binding NR1 subunits and two glutamate-binding NR2 subunits, of which there are four family members (NR2A, NR2B, NR2C, and NR2D). The four NR2 subunits each endow the receptor with different pharmacological and kinetic properties (Vicini et al., 1998; Yuan et al., 2009) . The NR2 subunits show distinct anatomical localization, which provides an opportunity to modify specific neuronal circuit function for therapeutic benefit using subunitselective antagonists and potentiators.
Identification of the first potent and subunit-selective inhibitor of NMDA receptor function, namely, the NR2B-selective antagonist ifenprodil, has allowed not only evaluation of the role this subunit plays in many brain functions and diseases but also has led to clinical trials of NR2B-selective antagonists for use in treatment-resistant depression (Preskorn et al., 2008) . However, despite the importance of NMDA receptors in many neurological disorders, antagonists that are more than 10-fold selective for NR2A, NR2C, or NR2D have not yet been identified. This largely reflects research efforts that have focused on the design of subunit-selective competitive antagonists. However, the agonist binding site is highly conserved across all glutamate-binding NR2 subunits, which has confounded attempts to engineer subunit selectivity among competitive antagonists. Similarly, channel blockers are similarly poorly selective for the various subunits (Dravid et al., 2007) , presumably due to structural conservation of the permeation pore. The lack of subunit-selective pharmacological tools for this receptor class has precluded experiments that might otherwise provide greater understanding of the functional roles of the NR2A, NR2C, and NR2D subunits. To address the need for new pharmacological tools, we developed an assay that can identify noncompetitive antagonists and modulators of NMDA receptor function. Here, we studied the NR2D subunit, which gives rise to a nondesensitizing response and is suited for assays based on fluorescence measurements of intracellular calcium. Validation screens with small focused libraries confirmed the utility of this assay and identified two classes of compounds (TRPV1 and histamine H3 receptor antagonists) as novel NMDA receptor antagonists. TRPV1 receptors, also known as vanilloid-1 receptors or capsaicin receptors, are nonselective cation channels that are activated by a range of physical and chemical stimuli, including heat, extracellular protons, and vanilloids (Romanovsky et al., 2009) . Histamine H3 receptors are expressed at high levels in the central nervous system, where they are presynaptic G protein-coupled receptors that regulate the release of a variety of neurotransmitters, including biogenic amines, acetylcholine, GABA, and glutamate (Haas et al., 2008) . The actions of histamine H3 receptor antagonists on NR2B-containing NMDA receptors could present potentially interesting opportunities in terms of drug development.
Materials and Methods
Generation and Selection of a Stable Cell Line Expressing NR1/NR2D Receptors. Baby hamster kidney (BHK)-21 cell lines stably expressing NR2D as well as NR1-1a (hereafter called NR1) under the control of a tetracycline-inducible promoter (Tet-On; Clontech, Mountain View, CA) were generated as described in Hansen et al. (2008) . The DNA constructs used were the rat NR1-1a in pTRE2 vector and rat NR2D in the pCI-IRES-bla vector (GenBank accession numbers U11418 and D13214, respectively) (Hansen et al., 2008) .
BHK-21 cells were maintained at 37°C, 5% CO 2 , and 95% relative humidity in Dulbecco's modified eagle medium containing GlutaMAX-I, 4500 mg/l glucose, and 110 mg/l sodium pyruvate (Invitrogen, Carlsbad, CA) supplemented with penicillin (100 units/ml), streptomycin (100 g/ml) (Invitrogen), 10% dialyzed fetal bovine serum (Invitrogen), 1 mg/ml G418 (Invitrogen), and 10 g/ml blasticidin S (Invivogen, San Diego, CA), as well as 200 M DL-2-amino-5-phosphonopentanoate (AP5) (Ascent Scientific, Princeton, NJ) and 200 M 7-chloro-kyneurenate (7-CKA) (Ascent Scientific) to prevent NMDA receptor-mediated cell death. Fura-2 imaging was used to confirm that the clonal cell line expressed functional NR1/NR2D receptors. Individual clones were grown for 48 h to approximately 90% confluence on 12-mm glass coverslips in the presence or absence of 2 g/ml doxycycline. Before imaging, the medium was removed and the cells were washed thoroughly with imaging buffer containing 150 mM NaCl, 3 mM KCl, 22 mM sucrose, 10 mM glucose, 2 mM CaCl 2 , and 10 mM HEPES at pH 7.4. The cells were loaded for 30 min at 37°C with 5 M Fura-2/acetoxymethyl ester and 1 M Pluronic F-127 solution made in imaging buffer. The glass coverslips were placed in a perfusion chamber and continually perfused with imaging buffer. NMDA receptors are Ca 2ϩ -permeable; thus, their activation gives rise to Ca 2ϩ influx and an increase in the intracellular Ca 2ϩ concentration. NMDA receptor responses were activated using 50 M glutamate and 50 M glycine in imaging buffer. As a positive control, 10 M ATP was used to activate endogenously expressed P2Y receptors, which are known to increase intracellular calcium. Intracellular Fura-2 was excited at 340 nm and 380 nm, and the ratio of the emissions at 510 nm was monitored using a BX51WI microscope (Olympus America Inc., Center Valley, PA) and a PTI IC200 intensified camera (PTI, Birmingham, NJ). The cell line that displayed a robust response to glutamate and glycine was expanded and frozen at Ϫ130°C.Na 2 HPO 4 , 0.44 mM KH 2 PO 4 , 4.17 mM NaHCO 3 , 5.56 mM D-glucose, and 20 mM HEPES at pH 7.4. The cells were then incubated in assay buffer supplemented with 100 l of Fluo-4 no-wash calcium assay dye solution (Invitrogen) for 30 min at 37°C according to the manufacturer's protocol. Unless otherwise stated, the dye solution also contained 30 M 7-CKA, a competitive glycine site antagonist, to prevent NMDA receptor-mediated cytotoxicity during dye loading. After incubation at 37°C, the cells were allowed to equilibrate to room temperature for 10 min before initiation of the assay. Changes in Fluo-4 fluorescence in response to addition of agonists, and test compounds were measured at 538 nm using a FlexStation II multimode plate reader (Molecular Devices, Sunnyvale, CA) with excitation at 485 nm and emission cut-off at 530 nm to minimize background fluorescence. Baseline fluorescence was measured for 20 s before the addition of test compound to the assay plate, and the peak fluorescence was measured after addition of the agonists and the test compounds. Peak fluorescence was represented as percent of the preagonist baseline fluorescence (100% ϫ F/F baseline ). Agonists and the test compound in a volume of 25 l were added to 100 l of assay buffer in the assay plate. Compound plates for the assay were prepared with assay buffer and five times the final compound concentration to account for the 1:5 dilution from the compound plate to the assay plate. The final concentrations of the agonist were kept at 100 M glutamate and 1 mM glycine. Test compounds were added to each well with agonists to yield a final well concentration of 10 M test compound in 0.9% DMSO.
Compounds, pK a Prediction, and Structural Overlay. All compounds from the library of pharmacologically active compounds (LOPAC) were obtained from Sigma-Aldrich (St. Louis, MO). All NMDA receptor-like antagonist (NRA) focused library compounds shown in Tables 1 to 3 were from Tocris Bioscience (Ellisville, MO), except for direct red and N- ((((4-chloroanalino) and N-{2-[(4-chlrophenyl) sulfanyl]ethyl}-2-(3-methylphenyl)acetamide and 3-(1,3-benzoxazol-2-ylthio)-1-(4-chlorophenyl)prop-2-en-1-one (Key Organics, Cornwall, UK), and levallorphan and phenylcyclohexamine derivatives (gifts from Dr. Stephen Holtzman, Emory University, Atlanta, GA). pK a values for capsazepine, clobenpropit, and iodophenpropit were calculated using ACD/pK a DB, version 9.03 (Advanced Chemistry Development, Inc., Toronto, ON, Canada). The Maestro suite, version 8.5 (Schrödinger, New York, NY) was used to do conformational search for ifenprodil using the OPLS-2005 force field (Jorgensen and Tirado-Rives, 2005) . The conformationally best energy-minimized structure of ifenprodil was chosen as reference compound, and clobenpropit, iodophenpropit, and capsazepine were subjected to conformational search by using OMEGA, version 2.0 (OpenEye Scientific Software, Santa Fe, NM). The resulting confirmations were superimposed with ifenprodil using rapid overlay of chemical structures (ROCS) (Hawkins et al., 2007) .
Two-Electrode Voltage-Clamp Electrophysiology. Two-electrode voltage-clamp (TEVC) recordings were performed on Xenopus laevis oocytes expressing NMDA (NR1/NR2A-D), ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (GluR1), and kainate (GluR6) receptors. cDNAs for rat NR1-1a (GenBank accession numbers U11418 and U08261), NR2A (GenBank accession number D13211), NR2B (GenBank accession number U11419), NR2C (GenBank accession number M91563), NR2D (GenBank accession number L31611), GluR1 (GenBank accession number X17184), and GluR6 (GenBank accession number Z11548) were provided by Drs. S. Heinemann (Salk Institute for Biological Studies, San Diego, CA), S. Nakanishi (Kyoto University, Kyoto, Japan), and P. Seeburg (University of Heidelberg, Heidelberg, Germany). The NR1(N616R) mutation and the NR2B mutant subunits were generated using the QuikChange site-directed mutagenesis kit (Stratagene, Cedar Creek, TX) according to the manufacturer's protocol and verified by DNA sequencing. The DNA construct encoding the amino-terminal domain deletion of the NR2B subunit (NR2B-⌬ATD) has been described previously ). Oocyte isolation and RNA injection were completed as described in detail previously (Traynelis et al., 1998) ; all protocols involving X. laevis were approved by the Emory University Institutional Animal Care and Use Committee. During TEVC recordings, oocytes were placed into a perfusion chamber and continually washed with recording solution containing 90 mM NaCl, 1 mM KCl, 0.5 mM BaCl 2 , 0.005 mM EDTA, and 10 mM HEPES at pH 7.4 (23°C). Glass electrodes had a tip resistance of 0.5 to 2.5 M⍀ and were pulled from thin-walled glass capillary tubes using a PP-83 puller (Narashige, East Meadow, NY). Voltage and current electrodes were filled with 0.3 and 3 M KCl, respectively. The current and voltage electrodes were connected to an OC-725C amplifier (Warner Instruments, Hamden, CT), which held the membrane potential of the oocytes at Ϫ40 mV during recording (unless otherwise stated). In the secondary screen, the inhibitors identified in the calcium imaging screen were purchased as powder, made into 20 mM stocks in DMSO, diluted to reach a final concentration of 10 M in recording solution containing 100 M glutamate and 30 M glycine. The final DMSO concentration was 0.05% (v/v).
Radioligand Binding. Human embryonic kidney 293 cells were transfected with human histamine H3 receptor cDNA [full-length isoform (445 amino acids) in pCI-neo; GenBank accession number NM_007232] using calcium phosphate precipitation. The plasmid RSV.TAg that encodes the simian virus 40 T antigen was used in transfections to increase receptor expression. Cells were harvested and homogenized in ice-cold TE buffer (50 mM Tris-HCl and 5 mM EDTA, pH 7.4) approximately 48 h after transfection, followed by 30-min centrifugation at 20,000g. The membrane pellets were homogenized and centrifuged one more time as described above. Final membrane pellets were frozen at Ϫ80°C until needed. For competition binding, membrane preparations were incubated with ϳ1.0 nM [ 3 H]N-␣-methylhistamine (PerkinElmer Life and Analytical Sciences, Boston, MA) in the presence or absence of increasing concentrations of ifenprodil. The binding reactions were incubated for 30 min at 23°C in a final volume of 0.5 ml of TE buffer. Nonspecific binding was defined with 30 M thioperamide. Binding reactions were terminated by filtration under vacuum onto Whatman GF/B filters (Brandel Inc., Gaithersburg, MD) followed by two washes with ϳ4 ml of ice-cold TE buffer, and bound radioligand was determined by liquid scintillation counting; for each of three independent experiments, measurements were made in duplicate. IC 50 values were determined by fitting to the Hill equation (one-site binding), and K i values were calculated using the Cheng-Prusoff equation. The previously published K d value of 0.5 nM for [
3 H]N-␣-methylhistamine binding to the human histamine H3 receptor was used to derive the K i value for ifenprodil (Witte et al., 2006) . Data Analysis. Data generated from measurements using the FlexStation II were analyzed using BioAssay software (CambridgeSoft Corporation, Cambridge, MA) to identify NR1/NR2D modulators. Systematic plate errors (a progressive increase in signal intensity across the plate moving from columns 1 to 12) were subtracted from raw data, and the average and standard deviation of the responses across each 96-well plate were calculated.
Concentration-response data for individual oocytes normalized to the response in the absence of inhibitor (100%) were fitted to the Hill equation:
where n H is the Hill slope, [X] is the compound concentration, and IC 50 is the half-maximally effective concentration of inhibitor. Fitted IC 50 values and Hill slopes from individual oocytes were used to calculate the mean and S.E.M. For graphical presentation, data points from individual oocytes were averaged and then fitted to the Hill equation and plotted together with the resulting curve. Unless otherwise stated, data are represented as mean Ϯ S.E.M.
Results
Assay Design and Optimization. We developed a screening assay specifically designed to identify novel ligands that modulate the function of NR2D-containing NMDA receptors by acting at sites other than the agonist binding sites. NR2D-containing recombinant NMDA receptors show little desensitization and are Ca 2ϩ -permeabletwo properties that should render them amenable to fluorescence-based optical assays that measure agonist-induced Ca 2ϩ accumulation in mammalian cells using multiwell formats. We previously made a BHK-21 cell line that expresses the NR1 subunit under the control of the Tet-On inducible expression system and constitutively expresses of the NR2D subunit (Hansen et al., 2008) . Previous studies indicate that stable expression of NMDA receptor subunits in heterologous expression systems can be highly cytotoxic (Cik et al., 1993) . To avoid this, cell culture medium was supplemented with competitive NMDA receptor antagonists (200 M AP5 and 200 M 7-CKA). NR1 expression, a requirement for functional NMDA receptors, was induced by doxycycline approximately 48 h before the assay (Fig. 1A ). Fura-2 calcium imaging in the doxycycline-induced NR1/NR2D cell line produced a glutamate EC 50 value (0.34 M) that was similar to that measured from TEVC recordings in oocytes (0.46 M), suggesting this cell line reproduces the pharmacological properties of NR1/NR2D (Fig. 1B) .
The development of a multiwell assay using Fluo-4 calcium imaging to assess NR1/NR2D receptor function is associated with problems due to activation of NR1/NR2D receptors by glutamate and glycine at submicromolar concentrations (Hansen et al., 2008) . Even low nanomolar concentrations of glutamate (with trace amounts of glycine) present in the assay buffer from the time of washing through the dye loading period are sufficient to activate NR1/NR2D receptors. This tonic activation can also elevate the baseline Ca 2ϩ concentration, which reduces the signal-to-noise ratio (Fig. 1C) . To circumvent this problem, we added the competitive glycine site antagonist 7-CKA (30 M) during dye loading. This low-affinity antagonist prevents cytotoxicity during dye loading and subsequent experiments by preventing prolonged NR1/NR2D receptor activation. In the assay, the antagonist 7-CKA virtually eliminated basal receptor activation, the amount of which can be quantified as the difference between the preagonist baseline fluorescent response and the fluorescent responses after addition of an uncompetitive open channel blocker (ϩ)-MK-801 (10 M). In addition, 30 M 7-CKA is easily displaced in the assay by addition of a high concentration of glycine (1 mM) coapplied with glutamate (100 M), which together lead to full activation of the NR1/ NR2D receptors (Fig. 1D ). Concentration-response data were generated within the assay format for the coagonists glutamate and glycine (data not shown). This showed that 1 mM glycine was sufficient to completely overcome the inhibition produced by the competitive glycine site antagonist 7-CKA (30 M) that was present during dye loading. The glutamate EC 50 value (0.23 M) is similar to that measured from Fura-2 calcium imaging using the same NR1/NR2D cell line (0.34 M) and TEVC recordings in oocytes expressing NR1/NR2D (0.46 M). The ZЈ value is a standard measure of variability for multiwell assays, and values above 0.5 are considered a good indication that an assay is suitable for single-well screening of test compounds (Zhang et al., 1999) . The ZЈ value is calculated using the following equation: (2) Our assays yielded favorable ZЈ values of 0.59 Ϯ 0.12 (mean of 16 assay plates Ϯ S.D.). Consistent with the acceptable ZЈ values, the secondary screen using a different assay (see below) confirmed the majority of the hits that were identified.
Assay Validation and Screening for Known NMDA Receptor Antagonists. The reliability of the assay was validated by screening the commercially available LOPAC-1280 library (1280 compounds; Sigma-Aldrich) and our own NMDA NRA-focused library of 520 compounds, many of which contained biaryl ring systems separated by nitrogencontaining linkers of varied length and rigidity. We anticipated that these compounds should have a higher probability of inhibiting NMDA receptors because they were selected based on similarity with the NR2B-selective antagonist ifenprodil. Compounds that altered the response of any given well compared with control wells on the same plate by more than 2.5-fold of the S.D. (calculated from all wells on the plate for LOPAC) or by more than 40% of the control response on the same plate (NRA-focused library) were selected for secondary screening using TEVC recordings of X. laevis oocytes expressing recombinant NR1/NR2D receptors. These selection criteria were empirically determined to reduce false positives, while maintaining a throughput that could reasonably be evaluated in the secondary screen.
The NRA-focused library included 13 known NMDA receptor antagonists, three competitive antagonists and 10 uncompetitive use-dependent channel blockers. The screen identified all 10 uncompetitive inhibitors but none of the competitive antagonists (Tables 1 and 2 ). The LOPAC library contains 14 known noncompetitive and uncompetitive NMDA receptor antagonists. The screen of the LOPAC library using NR1/NR2D expressing BHK-21 cells successfully identified the known noncompetitive NMDA receptor antagonist ifenprodil, which shows low potency at the NR2D subunit (Table 1 ). In addition, this screen identified the known uncompetitive NMDA receptor channel blockers (ϩ)-MK-801, (Ϫ)-MK-801, CNS-1102, memantine, dextramethorphan, dextrorphan, levallorphan, 3-methoxy-morphanin, (Ϯ)-allylnormetazoline, and (ϩ)-allylnormetazoline (Table 1) . Thus, the primary screen of the LOPAC library identified 11 of 14 of the known NMDA receptor non-and uncompetitive antagonists present in the library, all of which were subsequently validated by showing at least 25% inhibition in the TEVC secondary screen. In addition, two more NMDA receptor antagonists (metaphit and pentamidine) that missed the threshold of detection in the screen of the LOPAC library were identified in the screen of the NRA focused library (Table 1 ). The LOPAC library also contains 17 well known competitive NMDA receptor antagonists that act at either the glycine or glutamate binding site. Only one of these known competitive antagonists (5-fluoroindole-2-carboxylic acid) surpassed the 2.5 S.D. from the mean (Table 2) .
Together, the combined data obtained with these two small libraries suggest that the use of high concentrations of both glutamate and glycine identifies only 5% (1 of 19) of the competitive antagonists screened, whereas 95% (18 of 19) of the noncompetitive and uncompetitive antagonists tested were identified. The known uncompetitive antagonist (arcaine) that was not identified in the screen also did not inhibit NR1/NR2D receptor responses in TEVC recordings from oocytes. These results suggest the assay as described here is robust and should identify noncompetitive and uncompetitive NMDA receptor inhibitors with a high level of confidence.
Compound Screening for Novel NR2D Modulators. The primary screen of the NRA focused library of 520 compounds identified 70 inhibitors using a criteria of 40% inhibition (hit rate, 13.5%), including the 10 uncompetitive NMDA receptor antagonists. In total, 24 inhibitors were active in the TEVC secondary screen as defined by showing at least 25% inhibition at 10 M (confirmed hit rate 4.6%), 14 of which were not previously known to inhibit NMDA receptors. In total, 44 inhibitors (hit rate 3.4%) were identified in the primary screen of the LOPAC library, of which 27 compounds (confirmed hit rate, 2.1%) tested were found to be active in the secondary TEVC screen. This included 15 compounds that were not previously known to inhibit NMDA receptors. Table 3 shows all compounds in both libraries not previously reported to inhibit NMDA receptors, and Table 4 summarizes the screening hit rates for both test libraries.
Several of the compounds identified in these validation screens that were not previously known to inhibit NMDA receptors represent particularly intriguing classes of compounds, including the prototypical vanilloid receptor TRPV1 antagonist capsazepine and the histamine H3 receptor antagonists clobenpropit and iodophenpropit ( Fig. 2A) . We subsequently generated concentration-response data for these ligands at recombinant NR1/NR2A, NR1/NR2B, NR1/NR2C, NR1/NR2D, GluR1, and GluR6 receptors expressed in X. laevis oocytes (Fig. 2) . Table 5 summarizes the IC 50 values of these compounds for inhibiting recombinant NMDA receptors. Histamine H3 Receptor Antagonists Are NR2B-Selective NMDA Receptor Antagonists. The histamine H3 receptor antagonist clobenpropit showed high potency (1.0 M) at NMDA receptors that contained the NR2B subunit, even though the screen identified the compounds at cells expressing NR1/NR2D. The structurally related histamine H3 receptor antagonist iodophenpropit showed similar selectivity for NR1/NR2B. These two biaryl compounds show structural similarity to a series of thiosemicarbazide and amide derivatives recently described as NR2B antagonists (Mosley et al., 2009 ). To evaluate the extent to which the family of histamine receptor antagonists showed cross-reactivity with NMDA receptors, we assessed H1-, H2-, H3-, and H4-selective histamine receptor antagonists as well as some structurally related histamine receptor agonists against recombinant NR1/NR2A, NR1/NR2B, NR1/NR2C, and NR1/ NR2D receptors expressed in X. laevis oocytes. Only aminopotentidine (Table 6 ) and the isothioureas, such as clobenpropit and iodophenpropit (Table 5) , showed inhibition of recombinant NMDA receptors, with IC 50 values less than 10 M. The chemical structures of the histamine receptor ligands studied are shown in Figs. 2 and 3 .
(5) N-{2-͓(4-Chlrophenyl)sulfanyl͔ethyl}-2-(3-methylphenyl)
To evaluate the mechanism of action of clobenpropit and iodophenpropit as NMDA receptor antagonists, we first assessed whether inhibition could be surmounted by increasing concentration of the coagonists glutamate and glycine. Increasing the concentration of glutamate and glycine from 100 Table 5.   TABLE 5 Concentration-response data for novel NMDA receptors antagonists IC 50 Ϯ S.E.M. and Hill slopes (n H ) determined by TEVC recordings from X. laevis oocytes expressing the indicated receptors. n is the number of oocytes. At NR1/NR2A-D and mutant NR1/NR2B receptors, the compounds were coapplied with 100 M glutamate and 30 M glycine. At GluR1 and GluR6, the compounds were coapplied with 100 M glutamate. Oocytes expressing GluR6 were incubated for 5 min in 10 M concanavalin A. The oocytes were voltage-clamped at Ϫ40 mV. IC 50 Ͼ 100 M indicates that the compound showed some inhibition but less than 50% inhibition at 100 M. and 30 M, respectively, to 500 and 150 M did not reduce the extent of inhibition at NR1/NR2B receptors produced by a half-maximally effective concentration of clobenpropit or iodophenpropit, indicating block was insurmountable and thus noncompetitive (Fig. 4, A-C) . Inhibition of NR1/NR2B by capsazepine was also noncompetitive (Fig. 4D) . Evaluation of the current-voltage relationship suggested the majority of the inhibition of NR1/NR2B receptors by both clobenpropit and iodophenpropit was mediated by a voltageindependent mechanism (Fig. 4, E and F) . However, there was a significantly higher degree of inhibition at Ϫ60 mV than at Ϫ40 mV for both compounds, suggesting that these Table 5 . IC 50 values are in micromolar. IC 50 Ͼ 100 M indicates that the compound showed some inhibition, but less than 50% inhibition at 100 M. Hill slopes were 0.7 to 1.5, and the number of oocytes were 3 to 12 for all compounds. Chemical structures are shown in Fig. 4 .
Clobenpropit
H1 antagonists Astemizole Ͼ100 Ͼ100 Ͼ100 Ͼ100 Cetririzine Ͼ100 Ͼ100 Ͼ100 44 Ϯ 3 Clemastine 64 Ϯ 9 Ͼ100 Ͼ100 Ͼ100 Terfenadine 60 Ϯ 13 59 Ϯ 6 6 1 Ϯ 5 Ͼ100 Triprolidine Ͼ100 Ͼ100 Ͼ100 Ͼ100 H2 antagonists Aminopotentidine 5.1 Ϯ 0.5 8.4 Ϯ 1.6 Ͼ100 Ͼ100 Cimetidine N.E. Ͼ100 Ͼ100 Ͼ100 846 N.E. N.E. Ͼ100 Ͼ100 Tiotidine 43 Ϯ 4 1 6 Ϯ 1 5 1 Ϯ 5 5 4 Ϯ 9 H2/H3 antagonist Burimamide Ͼ100 N.E. N.E. N.E. H3 antagonists Conessine 44 Ϯ 9 5 4 Ϯ 9 Ͼ100 Ͼ100 3-(1H-Imidazol-4-yl) propyl-di(p-fluorophenyl) methyl ether Ͼ100 Ͼ100 Ͼ100 Ͼ100 Impentamine N.E. Ͼ100 Ͼ100 Ͼ100 ROS 234 80 Ϯ 6 3 7 Ϯ 3 Ͼ100 Ͼ100 Thioperamide Ͼ100 Ͼ100 Ͼ100 Ͼ100 H4 antagonists JNJ-10191584 N.E. Ͼ100 Ͼ100 Ͼ100 Histamine receptor agonists Dimaprit Ͼ100 Ͼ100 Ͼ100 Ͼ100 Histamine trifluoromethyl toluidide Ͼ100 37 Ϯ 4 Ͼ100 Ͼ100 Imetit 52 Ϯ 14 Ͼ100 Ͼ100 Ͼ100 Immepip N.E. Ͼ100 Ͼ100 Ͼ100
N.E., no significant effect at 100 M. Table 6 . HTMT, histamine trifluoromethyl toluidide.
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at ASPET Journals on October 19, 2017 jpet.aspetjournals.org compounds exhibit voltage-dependent block of NR1/NR2B receptors with low potency. This voltage-dependent component of the inhibition was undetectable for capsazepine on NR1/NR2B (Fig. 4G) . Capsazepine is uncharged at physiological pH, whereas both clobenpropit and iodophenpropit show ionizable imidazole rings with similar predicted pK a values of 7.3. In addition, the isothiourea are predicted to show pK a values of 7.6 and 8.3 for clobenpropit and iodophenpropit, respectively (see Materials and Methods). Thus, more than 50% of the molecules will be positively charged at pH 7.4, consistent with the observation of voltage-dependent pore block. To determine whether voltage-dependent block of NR1/NR2A receptors, which lack the ifenprodil binding site, accounts for all inhibition observed for iodophenpropit, we evaluated the current-voltage relationship of iodophenpropit inhibition. In contrast to NR1/NR2B receptors, iodophenpropit showed inhibition of NR1/NR2A that was entirely voltage-dependent (Fig. 4H) . These results suggest that clobenpropit and iodophenpropit act with high potency at the ifenprodil site on NR2B-containing receptors to inhibit function. They also inhibit both NR1/NR2A and NR1/NR2B receptors at lower potency by blocking the pore, and the potency of this block is enhanced at hyperpolarized potentials. Consistent with this idea, the potency of iodophenpropit at a membrane potential of Ϫ80 mV (IC 50 ϭ 0.4 Ϯ 0.1 M; n ϭ 6) was 3.5-fold higher compared with the potency at a mem- brane potential of Ϫ40 mV (IC 50 ϭ 1.4 Ϯ 0.2 M; n ϭ 15). For NR1/NR2A (and we predict NR1/NR2C and NR1/NR2D) that lack sensitivity to ifenprodil-like compounds, this voltagedependent block fully accounts for the observed inhibition. Histamine H3 Receptor Antagonists and Ifenprodil Share Structural Determinants for Selective Inhibition of NR2B-Containing NMDA Receptors. To evaluate the possibility that capsazepine, clobenpropit, and iodophenpropit can inhibit NR2B-containing NMDA receptors by acting at the ifenprodil binding site, we compared the molecular shapes and electrostatic potentials of these compounds by performing a conformational search using the OMEGA conformation generator (see Materials and Methods). These conformer pools were then analyzed with the program ROCS that provides a measure of molecular shape complementarity and electrostatic potential distribution overlap through maximization of shape overlap between two structures. Shape complementarity is calculated by means of a simple Tanimoto comparison (Ts) resulting in a score between 0.0 (no overlap) and 1.0 (identical shape). A score of Ts Ͼ0.7 suggests significant shape complementarity (Nicholls et al., 2004) . The structural alignments of ifenprodil with capsazepine, clobenpropit, and iodophenpropit are depicted in Fig. 5 . Ts scores compared with ifenprodil were 0.72, 0.77, and 0.73 for capsazepine, clobenpropit, and iodophenpropit, respectively. The ROCS scores, which include components of both shape and functional similarity, were 1.09, 1.02, and 0.99 for capsazepine, clobenpropit, and iodophenpropit, respectively. The good structural similarities and complementarities of capsazepine, clobenpropit, and iodophenpropit with ifenprodil support the idea that the compounds and ifenprodil access a common binding site on NR2B. Similarly, competition binding experiments showed that ifenprodil is capable of inhibiting [
3 H]N-␣-methylhistamine binding to recombinant histamine H3 receptors, with an IC 50 value of 17 Ϯ 3 M (n ϭ 3), corresponding to an estimated K i value of 5.7 Ϯ 0.9 M. This result further suggests some similarity between the binding sites for clobenpropit, iodophenpropit, and ifenprodil on histamine H3 receptors and NR2B.
We further explored the structural basis of the NR1/NR2B-selective inhibition by the histamine H3 receptor antagonists. However, the dual action (voltage-dependent channel block and NR2B-selective noncompetitive antagonism) of these compounds at NMDA receptors complicates a straightforward strategy using site-directed mutagenesis to identify the structural determinants for the NR2B-selective component of the inhibition. Initially, we compared the IC 50 values for capsazepine, clobenpropit, and iodophenpropit at wildtype NR1/NR2B with those at the NR1/NR2B-⌬ATD deletion mutant, which does not contain the amino-terminal domain of NR2B (Table 5) . Consistent with ifenprodil binding to the amino-terminal domain of NR2B (Perin-Dureau et al., 2002) , the IC 50 values for all three compounds were increased (i.e., lower potency) at NR1/NR2B-⌬ATD. However, the fold changes in IC 50 values were only moderate for capsazepine (9.1-fold), clobenpropit (7.4-fold), and iodophenpropit (2.5-fold) and not as large as might be expected if they only inhibited NR1/NR2B through a mechanism involving the amino-terminal domain. Comparison of the inhibition at holding potentials of Ϫ60 and Ϫ40 mV for clobenpropit and iodophenpropit at NR1/NR2B-⌬ATD revealed that the inhibition now display a pronounced voltage dependence ( Fig. 6A ; also see Fig. 4 , E and F, for comparison with wild type NR1/ NR2B), consistent with the hypothesis that the voltagedependent channel block mechanism of action for the compounds is responsible for their activity at NR1/NR2B-⌬ATD.
To minimize the contribution of voltage-dependent channel block to the inhibition of NR1/NR2B by the histamine H3 receptor antagonists, we took advantage of the N616R mutation in NR1, which has previously been shown to drastically reduce the potency of channel blockers (Kashiwagi et al., 2002) . The IC 50 values for clobenpropit inhibition of NR1(N616R)/NR2B and NR1(N616R)/NR2B-⌬ATD were increased 4.8-and 107-fold, respectively, which is consistent with the removal of channel block inhibition for NR1(N616R)/NR2B and removal of both channel block and NR2B-selective noncompetitive antagonism for NR1(N616R)/NR2B-⌬ATD ( Fig. 6B ; Table 5 ). We further evaluated the clobenpropit sensitivity of NR1(N616R) coexpressed with NR2B subunits that harbor amino-terminal domain mutations that have either been shown to reduce ifenprodil sensitivity (Mony et al., 2009) or are adjacent to residues that influence ifenprodil sensitivity (Fig. 6C) . All the evaluated mutations show a strikingly similar sensitivity to ifenprodil and clobenpropit inhibition, suggesting that the compounds share structural determinants for their activity. Together, these data are consistent with the idea that the histamine H3 receptor antagonists clobenpropit and iodophenpropit act by binding to the ifenprodil site on NR1/NR2B receptors.
Discussion
The most important finding of this study is that some ligands that bind the histamine H3 receptor can also bind the amino-terminal domain of the NR2B NMDA receptor subunit. The evidence for this is that highly potent histamine H3 receptor antagonists are NR2B-selective noncompetitive antagonists that are sensitive to the same mutations in the NR2B amino-terminal domain that alter the IC 50 values of (green) with the vanilloid receptor TRPV1 antagonist capsazepine, as well as the histamine H3 receptor antagonists clobenpropit and iodophenpropit. The conformationally best-minimized structure of ifenprodil was chosen as reference compound, and capsazepine, clobenpropit, and iodophenpropit were subjected to conformational search and superimposed with ifenprodil (see Materials and Methods). Shape complementarity is calculated by means of a simple Ts comparison, resulting in a score between 0.0 (no overlap) and 1.0 (identical shape). Ts scores compared with ifenprodil were 0.72, 0.77, and 0.73 for capsazepine, clobenpropit, and iodophenpropit, respectively. The ROCS scores, which include components of both shape and functional similarity, were 1.09, 1.02, and 0.99 for capsazepine, clobenpropit, and iodophenpropit, respectively. NR2B-selective ligands. This finding raises the possibility that compounds can be designed to potentially inhibit both receptors systems, which may have useful therapeutic effects on brain function.
Novel Assay for Noncompetitive NMDA Receptor Inhibitors. Stable expression of NMDA receptor subunits has long been known to be cytotoxic, and this has complicated attempts to develop reliable and robust multiwell assays for NMDA receptor modulators. Our initial attempts to develop a robust NR1/NR2D assay were hampered by cytotoxic accumulation of intracellular divalent cations due to activation of NR1/NR2D by nanomolar levels of glutamate and glycine present in the external solution during dye loading. In addition, this accumulation of intracellular divalent ions increased the baseline signal of the Ca 2ϩ -sensitive dye, thereby decreasing the apparent response amplitude during addition of agonist (Fig. 1, C and D) . We were able to circumvent this problem by adding the competitive glycine site antagonist 7-CKA during dye loading of the cells immediately preceding the fluorescence measurements. This reduced accumulation of intracellular Ca 2ϩ and thus improved cell conditions and the signal-to-noise ratio, leading to acceptable measured ZЈ values greater than 0.5. We further designed this assay to eliminate hits on the agonist binding sites, which increases the probability of selectively identifying noncompetitive antagonists. The competitive glycine site antagonist 7-CKA can be readily displaced by a high concentration of glycine (1 mM) to initiate the signal in the assay. This high concentration of glycine together with high concentration of glutamate (200-fold EC 50 ) reduces the likelihood that test ligands at 10 M will displace either coagonist. Implementation of the assay on two test libraries that contained known NMDA receptor antagonists revealed a high success rate in identifying noncompetitive inhibitors and successfully avoided hits from competitive antagonists, demonstrating that this strategy is effective.
Novel Noncompetitive NMDA Receptor Antagonists. Application of this assay to two small test libraries identified two histamine H3 receptor antagonists with structural similarity to known NR2B-selective antagonists with submicromolar IC 50 values. NR1/NR2B inhibition involved an intriguing mixed mechanism; components of inhibition involved both interactions with the ifenprodil binding site in the NR2B subunit and voltage-dependent channel block.
Histamine H3 receptors are primarily expressed in nervous tissue and clobenpropit binds to and competitively inhibits human histamine H3 receptors, with a pK i value of 8.5 (i.e., K i ϭ 3 nM); iodophenpropit acts as an antagonist at histamine H3 receptors, with a pK i value of 8.1 (K i ϭ 8 nM) (Lim et al., 2005) . Clobenpropit and iodophenpropit are well known pharmacological tools that are often used as histamine H3 receptor antagonists, although they are also known to act at other targets. In addition to their ability to interact with high potency and activate the closely related histamine H4 receptors, these ligands also have relatively high affinity for the serotonin 5-hydroxytryptamine 3 , ␣ 2 -adrenergic, and receptors (Leurs et al., 1995; Liu et al., 2001; Lim et al., 2005) . Furthermore, imidazole-containing compounds, which include clobenpropit and iodophenpropit, are often associated with an inherent risk of cytochrome P450 inhibition (Lin and Lu, 1998) . These and other off-target effects led to reduced interest in the development of this structural class of histamine H3 receptor antagonists for therapeutical purposes.
In the present study, we evaluated the extent to which the histamine receptor ligands other than clobenpropit and iodophenpropit showed cross-reactivity with NMDA receptors (Table 6 ; Fig. 3 ). We evaluated histamine H1, H2, H3, and H4 receptor antagonists as well as various agonists. Among these ligands, only clobenpropit and iodophenpropit showed the most potent inhibition of recombinant NMDA receptors (IC 50 Ͻ 2 M). These results suggest that histamine receptor ligands in general are not antagonists at NR2B-containing NMDA receptors. Whereas NR2B-selective effect is not a general feature of histamine receptor ligands, it is intriguing that histamine itself has been proposed to potentiate NMDA receptors in an NR2B-selective manner (Bekkers, 1993; Vorobjev et al., 1993; Williams, 1994; Burban et al., 2010) . The site of action of histamine on NMDA receptors is not fully resolved.
Our finding that clobenpropit and iodophenpropit can inhibit NR2B-containing NMDA receptors at submicromolar concentrations raises a number of interesting ideas. For example, an NR2B-selective antagonist (CP-101,606) has recently been shown to significantly improve symptoms in patients with treatment-resistant depression (Preskorn et al., 2008) . The onset of antidepressive effects was rapid, and the effect was sustained in patients for days after a single drug infusion. Compounds with histamine H3 receptor antagonist activity combined with inhibition of serotonin re-uptake have been considered as a useful antidepressant strategy (Barbier et al., 2007) . Combination of NR2B antagonist activity with histamine H3 receptor block and serotonin reuptake inhibition may improve the antidepressant properties of these classes of compounds.
Inhibition of histamine H3 receptors increases release of glutamate in corticostriatal pathway and hippocampus (for review, see Haas et al., 2008) , which would be detrimental under neuropathological conditions that involve excitotoxicity in these regions. However, inhibition of histamine H3 receptors also increases release of the inhibitory transmitter GABA that could be considered beneficial under the same conditions (for review, see Haas et al., 2008) . Consequently, it could be hypothesized that synergistic effects may be obtained by combining NMDA receptor inhibition with histamine H3 receptor antagonism. Histamine H3 receptor antagonists are known to be anticonvulsant in several models of seizures (Fischer and van der Goot, 1998) . Similarly, NR2B-selective NMDA receptor antagonists also show anticonvulsant properties (Wlaź et al., 1999; Mares and Mikulecka, 2009) . These results support the idea that a compound that can block both of these two receptor classes may possess synergistic anticonvulsant activity. Furthermore, both clobenpropit (Dai et al., 2007) and NR2B antagonists show neuroprotective properties (Tamura et al., 1993) , further creating the opportunity for synergistic actions of dual antagonists of both histamine H3 receptors and NR2B-containing NMDA receptors.
Pharmacological Selectivity of Histamine H3 Receptor Antagonists. Our findings reinforce the idea that care is warranted in the interpretation of data with clobenpropit and iodophenpropit (Leurs et al., 1995; Liu et al., 2001; Lim et al., 2005) . Although clobenpropit has a K i value at histamine H3 receptors that suggests at least 100-fold higher potency than the measured IC 50 value at NR1/NR2B, the extent of histamine H3 receptor inhibition by the competitive antagonist clobenpropit will depend on the extracellular concentration of histamine. This means that the IC 50 value for inhibition of neuronal responses to histamine may lie closer to the IC 50 value for actions at the NR1/NR2B receptor. Thus, studies that use clobenpropit or iodophenpropit at unknown brain concentrations may inadvertently be causing some degree of inhibition of NR2B-containing NMDA receptors. It is possible that analogs of histamine H3 receptor antagonists currently under development could have higher potency at NR1/NR2B receptors, which could have important implications. Finally, the vanilloid receptor TRPV1 antagonist capsazepine is often used at a concentration of 10 M, which is half-maximally effective at inhibiting NR2B-containing NMDA receptors. This cross-reactivity may contribute to results in reports that capsazepine shows interactions with the glutamatergic system or is neuroprotective (Ray et al., 2003; Zanchet and Cury, 2003; Peng et al., 2008) .
In summary, we have identified intriguing cross-reactivity between certain histamine H3 receptor antagonists and NR2B-containing NMDA receptors. The activity of histamine H3 receptor ligands at NMDA receptors presents several potentially interesting opportunities in terms of drug development.
